Lupus study is now open for new participants

Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus

Patient must meet eligibility criteria as outlined below:

Note: additional eligibility criteria will be reviewed over the phone with the patient.

• Age: at least: 18 – 64 year old
• Diagnosed with systemic lupus for at least 6 months
• Be able to adhere to study schedule: every two weeks

Study design:

• Duration of study: approx. 1 year
• Investigational drug: ALX-0061 administered subcutaneously (under the skin with a small needle)
• Visits to the study clinic (1501 N. Campbell Ave., CATS) include clinical evaluation, disease activity assessment, and laboratory sampling
• Study related medical care and services are provided at no cost to study participants